Medical experts fear an organisational reshuffle in the European Commission will prioritise the economics of health care over patients' well-being, with significant implications for combating chronic diseases.
Incoming EU commission president Jean-Claude Juncker moved the health technology and pharmaceutical policy services from the Commission’s health directorate to the more lobby-friendly internal market directorate.
The services of the European Medicines Agency is responsible f...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? Login